Naquera, Spain

Vicente Felipo

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2017-2019

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Mind of Vicente Felipo

Introduction

Vicente Felipo, an accomplished inventor based in Naquera, Spain, has made significant contributions to the medical field through his innovative patent developments. With a focus on steroid compounds, Felipo's work aims to advance treatment options for complex health conditions.

Latest Patents

Vicente Felipo holds two notable patents. His latest invention involves a steroid compound specifically designed for the treatment of hepatic encephalopathy. This invention introduces the steroidal compound 3α-ethynyl-3β-hydroxyandrostan-17-one oxime, or a pharmaceutically acceptable salt thereof, which offers a new therapeutic approach for managing this serious liver-related condition.

Career Highlights

Felipo is currently associated with Umecrine Cognition AB, a company dedicated to the development of treatments for cognitive dysfunction. His work at Umecrine Cognition has been pivotal in exploring how innovative compounds can aid patients suffering from hepatic encephalopathy and potentially improve their quality of life.

Collaborations

Throughout his career, Vicente Felipo has had the privilege of collaborating with respected colleagues in the field, including Magnus Doverskog and Hanns Möhler. These partnerships reflect the importance of teamwork and shared knowledge in the pursuit of advancing medical innovations.

Conclusion

In summary, Vicente Felipo's inventive spirit and dedication to medical research exemplify the critical role inventors play in developing solutions for complex health issues. His contributions not only enhance current treatment methodologies but also inspire future innovations in the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…